Health Condition 1: null- Male pattern of hair loss
Conditions
Interventions
Intervention1: Hair 4 u: fixed dose 1.5% Aminexil and 5% Minoxidil topical solution applied twice daily for 24 weeks
Control Intervention1: 5% Minoxidil topical solution: 5% Minoxidil topical solution
Sponsors
Glenmark Pharmaceuticals Ltd
Eligibility
Inclusion criteria
Inclusion criteria: Male patients of age more than 18 to 50. Presence of androgenetic alopecia based on the Norwood Hamilton Scale Written informed consent by patient. Patient willing to follow up.
Exclusion criteria
Exclusion criteria: Alopecia areata, alopecia totalis, alopecia universalis and alopecia diffusa. Scarring of the scalp or any other condition or disease of the scalp or hair, including diseases of the hair shaft and inability to discontinue use of hair weaving. Use of the following during the 6 months prior to screening: ?X Minoxidil (oral or topical) ?X Drugs with anti-androgenic properties (e.g., cyproterone acetate, spironolactone, ketoconazole, flutamide, bicalutamide). Cimetidine cannot be used during the study but is not an excluded drug when used during the previous 6 months. ?X Drugs potentially causing hypertrichosis (e.g., cyclosporine, diazoxide, phenytoin psoralens) ?X Anabolic steroids ?X Lithium and phenothiazines Use of systemic steroids for more than 14 days within the past 2 months prior to enrollment in the study. Use of isotretinoin, radiation to the scalp, or chemotherapy within the past year. Known sensitivity to the investigational product
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Grade of balding based on hamilton scale and photographs Hair Density Anagen and Telogen ratio Timepoint: 12-24 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| nilTimepoint: nil | — |
Countries
India
Contacts
Public ContactDr CR Srinivas
Outcome results
None listed